
|Videos|February 4, 2019
Overcoming Challenges in Treating Patients With Triple-Negative Breast Cancer
Author(s)Stacy L. Moulder, MD
Stacy L. Moulder, MD, discusses the challenges in drug development for triple-negative breast cancer, specifically in the neoadjuvant setting.
Advertisement
Stacy L. Moulder, MD, professor of breast medical oncology at The University of Texas MD Anderson Cancer Center, discusses the challenges in drug development for triple-negative breast cancer (TNBC), specifically in the neoadjuvant setting.
Approximately 50% of patients with TNBC are sensitive to standard chemotherapy, says Moulder, and they do not need the additional toxicities of certain investigational agents.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































